Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treatment of skin disorders

a technology for skin disorders and compositions, applied in drug compositions, antibody medical ingredients, peptides, etc., can solve the problems of inconvenient other types of therapy, such as ultraviolet light therapy, and limited systemic therapy for psoriasis, and achieve the effect of uncommon undesirable

Inactive Publication Date: 2018-02-15
ABBVIE BIOTECHNOLOGY LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides improved methods for treating psoriasis, reducing disease severity, and improving quality of life for patients with the condition. The methods involve administering a TNFα inhibitor, such as a human TNFα antibody, to the patient. This can result in a significant improvement in the patient's DLQI score, a decrease in their Physician's Global Assessment score, and an improvement in their Psoriasis Area and Severity Index score. Overall, the invention offers a promising treatment option for patients with psoriasis.

Problems solved by technology

Treatment of psoriasis with systemic therapy, such as methotrexate or cyclosporine, or biologic therapy, such as efalizumab, can be limited by lack of efficacy or precluded by side effects.
Other types of therapy, for example ultraviolet light therapy, is often inconvenient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treatment of skin disorders
  • Methods and compositions for treatment of skin disorders
  • Methods and compositions for treatment of skin disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Rapid Improvement in Functional Limitations of Patients with Moderate to Severe Chronic Plaque Psoriasis Treated with Adalimumab

[0327]Psoriasis affects approximately 1-3% of the worldwide population. Moderate to severe disease is associated with psoriatic lesions on >3% body surface area. Clinical manifestations of moderate to severe psoriasis can severely limit a patient's physical function.

[0328]Efficacy and safety of adalimumab was evaluated in a 48-week extension trial conducted at eighteen sites. The study was a randomized, double-blind, placebo-controlled, multi-center clinical trial, wherein patients were randomized to one of three treatment groups. The three treatment groups consisted of the following:[0329]1. 80 mg adalimumab at baseline (week 0) and 40 mg at week 1 followed by 40 mg every other week (eow) starting at week 3 (referred to as ada 40 mg eow);[0330]2. 80 mg adalimumab at baseline (week 0) and 80 mg at week 1 followed by 40 mg weekly starting at week 2 (referred...

example 2

Efficacy and Safety of Adalimumab Treatment of Chronic Plaque Psoriasis in Patients Who Meet Some Criteria for Biological Interventions in Accordance with British Association of Dermatologists Guidelines

[0343]The British Association of Dermatologists (BAD) has published guidelines for the treatment of psoriasis with approved biologic interventions such as infliximab, etanercept, and efalizumab. This subanalysis study measured the efficacy of to adalimumab in patients from the above study who qualified for biologic treatment under these guidelines.

[0344]The efficacy and safety of adalimumab in patients eligible for biologic therapy under selected BAD guidelines was evaluated. The selected BAD guidelines included a PASI ≧10 and a DLQI >10. The efficacy outcome measures were PASI, PGA, and DLQI. FIG. 1 shows the study design.

[0345]The following analytic methods were employed in this subanalysis: modified intention to treat analyses were preformed on all randomized patients receiving at...

example 3

Recent History of Systemic or Biologic Therapy Does Not Adversely Affect Adalimumab Efficacy and Safety in Patients with Moderate to Severe Chronic Plaque Psoriasis

[0353]Psoriasis is a chronic, inflammatory proliferative disease of the skin that affects 1-3% of the general population (Greaves and Weinstein (1995) N Engl J Med 332: 581). Treatment of moderate to severe psoriasis with systemic therapy such as methotrexate or cyclosporine or biologic therapy such as efalizumab can be limited by lack of efficacy or precluded by side effects. Ultraviolet light therapy is often inconvenient.

[0354]Previous studies demonstrated adalimumab is effective in treating moderate to severe plaque psoriasis (Ps), with an acceptable safety profile. Some study patients had a recent (within past 12 months) history of exposure systemic or biologic (except TNF antagonists) therapy, but could enroll if systemic therapy stopped at least 4 wks prior to study (at least 12 wks for biologics). The impact of pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNFα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 12 / 646891, filed Dec. 23, 2009, which is continuation-in-part of U.S. application Ser. No. 12 / 352503, filed Jan. 12, 2009, and U.S. application Ser. No. 12 / 402408, filed Mar. 11, 2009. U.S. application Ser. No. 12 / 646891 claims the benefit of priority to U.S. Provisional Application No. 61 / 140606, filed Dec. 23, 2008, and U.S. Provisional Application No. 61 / 183446, filed Jun. 2, 2009. U.S. application Ser. No. 12 / 352503 is a continuation of U.S. application Ser. No. 12 / 130,831, filed on May 30, 2008, which claims the benefit of priority to U.S. Provisional Application No. 60 / 932914 filed on Jun. 1, 2007; U.S. Provisional Application No 61 / 011538, filed Jan. 17, 2008; U.S. Provisional Application No. 61 / 024122, filed Jan. 28, 2008; and U.S. Provisional Application No. 61 / 128498, filed May 22, 2008. U.S. application Ser. No. 12 / 402408 is a continuation of U.S application Ser. No. 11 / 880,433, file...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/24A61K39/00
CPCA61K2039/545C07K2317/56C07K2317/565C07K16/241A61P17/06Y02A50/30
Inventor OKUN, MARTIN M.HOFFMAN, REBECCA S.BARKER, JONATHAN
Owner ABBVIE BIOTECHNOLOGY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com